Nilotinib.
Deininger
Michael W
MW
Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, L592, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA. deininge@ohsu.edu
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D002986:Clinical Trials as Topic; D000069439:Dasatinib; D004353:Drug Evaluation, Preclinical; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008495:Medical Oncology / Q000379:methods*; D008956:Models, Chemical; D010879:Piperazines / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011743:Pyrimidines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D000069439:Dasatinib